The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor compound, alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://ztndz.com/story28949161/retatrutide-and-nicotinamide-adenine-dinucleotide-a-integrated-approach-to-physiological-health